[Corrigendum] Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models

• Authors:
  • Ronald A. Lubet
  • Vernon E. Steele
  • M. M. Juliana
  • Ann Bode
  • Fariba Moeinpour
  • Clinton J. Grubbs

• View Affiliations

  
  Affiliations: Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20852, USA, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35294, USA, Division of Cancer Biomarkers and Drug Resistance, University of Minnesota Hormel Institute, Austin, MN 55912, USA
• Published online on: October 17, 2018     https://doi.org/10.3892/or.2018.6802
• Pages: 718-718

• Copyright : © Lubet et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Article